232 related articles for article (PubMed ID: 36189576)
21. Evaluation of Leukocytes, B and T Lymphocytes, and expression of CD200 and CD23 on B lymphocytes in Patients with Atopic Dermatitis on Dupilumab Therapy-Pilot Study.
Čelakovská J; Čermáková E; Boudková P; Andrýs C; Krejsek J
Dermatol Ther (Heidelb); 2023 May; 13(5):1171-1192. PubMed ID: 37097547
[TBL] [Abstract][Full Text] [Related]
22. The association between eosinophils (CD16
Čelakovská J; Čermáková E; Boudková P; Andrýs C; Krejsek J
Dermatol Ther (Heidelb); 2023 May; 13(5):1193-1210. PubMed ID: 37071375
[TBL] [Abstract][Full Text] [Related]
23. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
Guttman-Yassky E; Bissonnette R; Ungar B; Suárez-Fariñas M; Ardeleanu M; Esaki H; Suprun M; Estrada Y; Xu H; Peng X; Silverberg JI; Menter A; Krueger JG; Zhang R; Chaudhry U; Swanson B; Graham NMH; Pirozzi G; Yancopoulos GD; D Hamilton JD
J Allergy Clin Immunol; 2019 Jan; 143(1):155-172. PubMed ID: 30194992
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects.
Li Z; Radin A; Li M; Hamilton JD; Kajiwara M; Davis JD; Takahashi Y; Hasegawa S; Ming JE; DiCioccio AT; Li Y; Kovalenko P; Lu Q; Ortemann-Renon C; Ardeleanu M; Swanson BN
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):742-755. PubMed ID: 32348036
[TBL] [Abstract][Full Text] [Related]
25. Exploration of biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab: A study protocol.
Nakahara T; Izuhara K; Onozuka D; Nunomura S; Tamagawa-Mineoka R; Masuda K; Ichiyama S; Saeki H; Kabata Y; Abe R; Ohtsuki M; Kamiya K; Okano T; Miyagaki T; Ishiuji Y; Asahina A; Kawasaki H; Tanese K; Mitsui H; Kawamura T; Takeichi T; Akiyama M; Nishida E; Morita A; Tonomura K; Nakagawa Y; Sugawara K; Tateishi C; Kataoka Y; Fujimoto R; Kaneko S; Morita E; Tanaka A; Hide M; Aoki N; Sano S; Matsuda-Hirose H; Hatano Y; Takenaka M; Murota H; Katoh N; Furue M
Medicine (Baltimore); 2020 Sep; 99(38):e22043. PubMed ID: 32957324
[TBL] [Abstract][Full Text] [Related]
26. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
27. Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab.
Kariyawasam HH
Expert Rev Clin Immunol; 2020 Dec; 16(12):1115-1125. PubMed ID: 33148074
[No Abstract] [Full Text] [Related]
28. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.
Hamilton JD; Suárez-Fariñas M; Dhingra N; Cardinale I; Li X; Kostic A; Ming JE; Radin AR; Krueger JG; Graham N; Yancopoulos GD; Pirozzi G; Guttman-Yassky E
J Allergy Clin Immunol; 2014 Dec; 134(6):1293-1300. PubMed ID: 25482871
[TBL] [Abstract][Full Text] [Related]
29. Safety of dupilumab in a 5-month-old infant with severe atopic dermatitis.
Havele SA; Khurana MC; McMahon P; Murthy AS; Perman MJ; Treat JR
Pediatr Dermatol; 2022 Mar; 39(2):291-294. PubMed ID: 35434859
[TBL] [Abstract][Full Text] [Related]
30. A case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab.
Jiang X; Ye J; Wu X; Zhu J; Chen S; Cheng H
Inflamm Res; 2023 Apr; 72(4):875-878. PubMed ID: 36912915
[TBL] [Abstract][Full Text] [Related]
31. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL; Bieber T; Guttman-Yassky E; Beck LA; Blauvelt A; Cork MJ; Silverberg JI; Deleuran M; Kataoka Y; Lacour JP; Kingo K; Worm M; Poulin Y; Wollenberg A; Soo Y; Graham NM; Pirozzi G; Akinlade B; Staudinger H; Mastey V; Eckert L; Gadkari A; Stahl N; Yancopoulos GD; Ardeleanu M;
N Engl J Med; 2016 Dec; 375(24):2335-2348. PubMed ID: 27690741
[TBL] [Abstract][Full Text] [Related]
32. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy.
D'Erme AM; Romanelli M; Chiricozzi A
Drug Des Devel Ther; 2017; 11():1473-1480. PubMed ID: 28553077
[TBL] [Abstract][Full Text] [Related]
33. Dupilumab: First Global Approval.
Shirley M
Drugs; 2017 Jul; 77(10):1115-1121. PubMed ID: 28547386
[TBL] [Abstract][Full Text] [Related]
34. Anti-IL-4Ralpha monoclonal antibody dupilumab mimics ulcerative colitis: a case report.
Shimodaira Y; Takahashi S; Iijima K
BMC Gastroenterol; 2021 May; 21(1):207. PubMed ID: 33964871
[TBL] [Abstract][Full Text] [Related]
35. Dupilumab for Atopic Dermatitis-From Clinical Trials to Molecular and Cellular Mechanisms.
Cabanillas B
Dermatitis; 2023; 34(1):21-28. PubMed ID: 36705657
[TBL] [Abstract][Full Text] [Related]
36. Ocular surface disease associated with dupilumab treatment for atopic diseases.
Utine CA; Li G; Asbell P; Pflugfelder S; Akpek E
Ocul Surf; 2021 Jan; 19():151-156. PubMed ID: 32439390
[TBL] [Abstract][Full Text] [Related]
37. Dupilumab for treatment of atopic dermatitis.
Seegräber M; Srour J; Walter A; Knop M; Wollenberg A
Expert Rev Clin Pharmacol; 2018 May; 11(5):467-474. PubMed ID: 29557246
[TBL] [Abstract][Full Text] [Related]
38. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
Wollenberg A; Beck LA; Blauvelt A; Simpson EL; Chen Z; Chen Q; Shumel B; Khokhar FA; Hultsch T; Rizova E; Rossi AB; Graham NMH; Pirozzi G; Lu Y; Ardeleanu M
Br J Dermatol; 2020 May; 182(5):1120-1135. PubMed ID: 31407311
[TBL] [Abstract][Full Text] [Related]
39. [Psoriasis in dupilumab-treated atopic dermatitis].
Senner S; Eicher L; Aszodi N; Prinz JC; French LE; Wollenberg A
Hautarzt; 2020 May; 71(5):383-386. PubMed ID: 32179945
[TBL] [Abstract][Full Text] [Related]
40. The anti-IL-4 receptor alpha antibody dupilumab: facing a new era in treating atopic dermatitis.
Tsianakas A; Luger TA
Expert Opin Biol Ther; 2015; 15(11):1657-60. PubMed ID: 26457448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
